Quintiles will add TMAC's medical science liaison (MSL) capabilities to its existing field-based medical solutions, providing customers with additional experience to engage opinion leaders and encourage a heightened knowledge of research, products and devices. TMAC will be able to leverage Quintiles' clinical educators with its clients to facilitate ongoing education of healthcare professionals, patients and caregivers throughout the U.S.
"Today, more than ever before, biopharmaceutical companies looking to commercialize products in the U.S. are focused on demonstrating the value and benefits of their products to an increasingly diverse range of stakeholders," said Daryl Gaugler, senior vice president, commercial solutions at Quintiles. "This collaboration will extend and enhance our ability to deliver integrated commercialization programs for our customers, including for small to medium-sized companies, as they consider their options for developing capabilities in the U.S. market."
Quintiles and TMAC will continue to provide customers with integrated, multi-disciplinary teams, but now with an added breadth of experience. Each company will utilize the services of the other to bolster existing capabilities and provide comprehensive solutions to U.S. customers.
"Requirements for medical affairs activities are expanding across the product life cycle," said Evan Demestihas, M.D., chief executive officer, TMAC. "Working with companies like TMAC and Quintiles provides customers with benefits in terms of strategic oversight, speedy deployment and operational flexibility, while maintaining the discipline-specific and therapy area experience that are essential to medical affairs teams."